0000950170-23-066796.txt : 20231129 0000950170-23-066796.hdr.sgml : 20231129 20231129164900 ACCESSION NUMBER: 0000950170-23-066796 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231127 FILED AS OF DATE: 20231129 DATE AS OF CHANGE: 20231129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bedrosian Camille L CENTRAL INDEX KEY: 0001326969 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 231452989 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 ownership.xml 4 X0508 4 2023-11-27 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001326969 Bedrosian Camille L C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 false true false false Chief Medical Officer false Common Stock 2023-11-27 4 A false 58333 0.00 A 58333 D Stock Option (Right to Buy) 12.93 2023-11-27 4 A false 162500 0.00 A 2033-11-26 Common Stock 162500 162500 D The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 annual installments, with the first installment vesting on December 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. 25% of the shares subject to the option shall vest and become exercisable on December 1, 2024, with the remainder vesting in a series of 36 successive monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. /s/ Joshua B. Cohen, as Attorney in Fact 2023-11-29